Top Markets
#1 Helium Helium +83.36%
#2 Seeker Seeker +52.14%
#3 Pons Pons +36.63%
#4 UnifAI Network UnifAI Network +29.95%
#5 TENDIES TENDIES +27.32%
#6 Tensor Tensor +23.80%
#7 Zylo Ecosystem Zylo Ecosystem +23.78%
#8 Bounce Bounce +17.72%
#9 pipedog pipedog +16.96%
#10 Songbird Songbird +15.11%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
CHO Pharma, Inc. CHO Pharma, Inc.

CHO Pharma, Inc.

6586
Rank in Stocks #11104
CHO Pharma, Inc., a biotechnology firm headquartered in Taipei City, Taiwan,... CHO Pharma, Inc., a biotechnology firm headquartered in Taipei City, Taiwan, specializes in the research and development of innovative therapeutic solutions. Central to its operations is an advanced glycoengineering platform. This proprietary technology facilitates the creation of several key therapeutic modalities, including SAR-based glycoengineered "biobetters," site-specific antibody-drug conjugates (ADCs), and novel antibodies and vaccines designed to target unique carbohydrate antigens. The company also offers CHOptimax, an innovative in vitro enzymatic single-step process. This technology allows for the precise transformation of unconjugated antibodies into either glycoengineered biobetters or ADCs. CHO Pharma boasts a robust and diverse pipeline of drug candidates spanning various therapeutic areas, all leveraging its glycoengineering expertise. Currently, several programs are in clinical development: CHO-H01 is undergoing Phase I/IIa trials for refractory non-Hodgkin lymphoma, while CHO-A04, a humanized monoclonal antibody, has entered Phase I trials targeting a range of tumor and cancer stem cells. Additionally, CHO-V08 is being developed as a vaccine against Klebsiella pneumoniae. In the preclinical stage, CHO Pharma is advancing CHO-H02, an agent designed to address various solid tumors including breast, bladder, pancreatic, ovarian, and gastric cancers. Another preclinical asset, CHO-H03, is an antibody drug being investigated for inflammatory conditions associated with autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease. Established in 2012, CHO Pharma continues to innovate from its base in Taipei City, Taiwan.
Share Price
$3.47
Last synced: 2026-08-28
Market Cap
$741.78M
Change (1 day)
-0.91%
Change (1 year)
181.14%
Country
TW
Trade CHO Pharma, Inc. (6586)

Category

Healthcare
Revenue for CHO Pharma, Inc. (6586)
Revenue in Aug 2026 TTM: 0
According to CHO Pharma, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for CHO Pharma, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH